ProMed Pharma Announces Second Dedicated Manufacturing Suite Agreement at Niagara Lane Facility
Summary
ProMed Pharma has secured a second dedicated manufacturing suite agreement at its Niagara Lane facility in Plymouth, Minnesota. The new suite will support highly potent active pharmaceutical ingredients and complex generic drug products. The facility is built for specialized containment, cGMP compliance, and future commercial production. The deal shows continued demand for purpose-built pharmaceutical manufacturing capacity and expands ProMed’s ability to support long-acting and sustained-release therapies.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected